Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Cytiva US LLC is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, showing a slight concentration of the workload. The prosecution is focused within 1 distinct art unit, suggesting that the company's current applications are technically similar or closely related within the Biotechnology & Pharmaceuticals field.
The busiest examiner for this portfolio is HOWELL, MARC C, who is currently assigned 2 busiest examiner pending actions. This indicates that HOWELL, MARC C is reviewing a significant portion of the 3 pending office actions. The remaining pending office action is handled by the other of the 2 distinct examiners.
For a practitioner, the concentration in 1 distinct art unit may allow for a more consistent prosecution strategy across the 3 pending office actions. However, the fact that HOWELL, MARC C manages 2 busiest examiner pending actions means that his specific examination style will be a primary factor in the portfolio's overall progress. Success in the 1 distinct art unit will depend heavily on addressing the concerns raised in the 2 busiest examiner pending actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, MARC C | 2 | 68.7% | +24.5% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18624940 | SMALL VOLUME MIXING DEVICE | HOWELL, MARC C | — |
| 18624918 | SMALL VOLUME MIXING DEVICE HARDWARE | HOWELL, MARC C | — |
| 18087173 | VIRUS SEPARATION | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18624940 | SMALL VOLUME MIXING DEVICE | HOWELL, MARC C | — |
| 18624918 | SMALL VOLUME MIXING DEVICE HARDWARE | HOWELL, MARC C | — |
| 18087173 | VIRUS SEPARATION | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18624940 | SMALL VOLUME MIXING DEVICE | HOWELL, MARC C | — | §102§103 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18624918 | SMALL VOLUME MIXING DEVICE HARDWARE | HOWELL, MARC C | — | §102§103 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18087173 | VIRUS SEPARATION | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Non-Final OA | — | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCytiva US LLC has 3 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Marc C Howell has the most, with 2 of Cytiva US LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
